Sensory-Evoked Cortical Gamma Oscillation for Alzheimer's Disease

This trial explores a new approach for Alzheimer's Disease using a device called GammaSense. The device provides sensory stimulation to produce brain waves (gamma oscillation) that may aid memory and thinking skills. Participants will use the device daily for eight weeks. It suits individuals 60 and older who have Alzheimer's and can communicate in English. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance memory and thinking skills.

The trial information does not specify whether you need to stop taking your current medications.

Research has shown that the GammaSense Stimulation device is generally safe for people. An early study found that patients handled the one-hour daily therapy well and suggested that the device might help improve brain function. Another study tested daily 40 Hz stimulation in five Alzheimer's patients and found that the treatment was well-tolerated over time. The GammaSense device uses non-invasive sensory stimulation, meaning it doesn't require surgery or medication. This method aims to support brain health without causing harm. Overall, the evidence so far indicates that the treatment is safe for people with Alzheimer's.¹²³⁴⁵

The GammaSense Stimulation device is unique because it uses gamma frequency sensory stimulation, a novel approach for treating Alzheimer's disease. Unlike current treatments that primarily focus on managing symptoms, this method aims to target the brain's electrical activity to potentially alter disease progression. Researchers are excited about this treatment as it introduces a non-invasive way to engage with the brain's natural rhythms, possibly offering a new avenue for therapy that could complement or enhance existing options.

Research has shown that stimulating certain brain waves, called gamma oscillations, at 40 Hz using sensory devices can aid in Alzheimer's Disease. Studies in animals and humans suggest that this 40 Hz stimulation might reduce harmful proteins linked to Alzheimer's, such as amyloid and tau. In a small study, five patients with mild Alzheimer's safely used this stimulation daily for two years and experienced positive effects. In this trial, participants with Alzheimer's Disease will receive daily gamma frequency sensory stimulation using the GammaSense Stimulation device for an 8-week period. GammaSense Stimulation aims to use these findings as a new way to support brain function and slow the progression of Alzheimer's.¹²⁴⁶⁷